A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America (EMPOWER)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03845400|
Recruitment Status : Active, not recruiting
First Posted : February 19, 2019
Last Update Posted : December 27, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The main aim of this study is to compare the HAE attack rate before and after lanadelumab treatment was started in persons with Hereditary Angioedeme Type I or II.
Data from participants will be collected for at least 24 months. Participants will report information in a smartphone application at study start and then every 3 months until the study ends; data will also be collected by the study doctor during routine clinic visits.
|Condition or disease|
|Hereditary Angioedema (HAE)|
|Study Type :||Observational|
|Actual Enrollment :||165 participants|
|Official Title:||An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)|
|Actual Study Start Date :||March 30, 2019|
|Estimated Primary Completion Date :||December 31, 2023|
|Estimated Study Completion Date :||December 31, 2023|
Type I or Type II HAE Participants
Participants with Type I or Type II HAE will be followed for 24 or 36 months depending upon enrollment date. Data collection will cease at the end of follow-up period, at the time of withdrawal, lost to follow-up, or death whichever comes first.
- Number of Hereditary Angioedema (HAE) Attacks [ Time Frame: From enrollment up to 36 months ]Number of HAE attacks before and after lanadelumab initiation will be reported.
- Dose of Lanadelumab Injections [ Time Frame: From enrollment up to 36 months ]Dose of lanadelumab injections used during the study will be reported.
- Frequency of Lanadelumab Injections [ Time Frame: From enrollment up to 36 months ]Frequency of lanadelumab injections during the study will be reported.
- Proportion of Injections Based on the Type of Administration of Lanadelumab [ Time Frame: From enrollment up to 36 months ]Proportion of injections based on the type of administration of lanadelumab (self, caregiver, health care provider [HCP], other) will be reported.
- Time From Diagnosis to Lanadelumab Initiation [ Time Frame: From enrollment up to 36 months ]Time from diagnosis of HAE attack(s) to lanadelumab treatment initiation will be reported.
- Proportion of Participants who Discontinue Lanadelumab [ Time Frame: From enrollment up to 36 months ]Discontinuation is defined as no documented lanadelumab use after at least 2 missing consecutive doses after the last date of injection, or documented as treatment discontinued by the physician. Proportion of participants who discontinue lanadelumab treatment will be reported.
- Number of Lanadelumab Injections Before Discontinuation per Reason for Injection [ Time Frame: From enrollment up to 36 months ]Discontinuation is defined as no documented lanadelumab use after at least 2 missing consecutive doses after the last date of injection, or documented as treatment discontinued by the physician. Number of injections administered by participant before discontinuation per reason for injection will be reported.
- Number of Hospitalizations due to Hereditary Angioedema (HAE) Attack(s) [ Time Frame: From enrollment up to 36 months ]Number of hospitalizations due to HAE attack(s) will be reported.
- Number of Emergency Room (ER) Visits due to Hereditary Angioedema (HAE) Attack(s) [ Time Frame: From enrollment up to 36 months ]Number of emergency room (ER) visits due to HAE attack(s) will be reported.
- Number of Physician Visits due to Hereditary Angioedema (HAE) Attack(s) [ Time Frame: From enrollment up to 36 months ]Number of physician visits due to HAE attack(s) will be reported.
- Rescue Medications Taken at Time of Hereditary Angioedema (HAE) Attack(s) [ Time Frame: From enrollment up to 36 months ]Number, type of rescue medications taken by the participants at the time of HAE attack(s) per the type of administration (self, caregiver, HCP, other) will be reported.
- Hereditary Angioedema (HAE) Attack Control Score Before and After Lanadelumab Initiation, as Measured by the Angioedema Control Test (AECT) [ Time Frame: From enrollment up to 36 months (every 3 months) ]AECT is a questionnaire and not a validated patient-reported outcome (PRO). HAE control score is evaluated as frequency of answers [very often, often, sometimes, seldom, not at all] to the following questions at record closest to enrollment date): 1. In the last 3 months, how often have you had angioedema? 2. In the last 3 months, how much has your quality of life been affected by angioedema? 3. In the last 3 months, how much has the unpredictability of your angioedema bothered you? 4. In the last 3 months, how well has your angioedema been controlled by your therapy?
- Angioedema Quality of Life (AE-QoL) Score [ Time Frame: From enrollment up to 36 months (every 3 months) ]The AE-QoL is developed to measure health-related quality of life (HRQoL) impairment in participants with recurrent angioedema. It is a self-administered PRO designed for adults aged 18 years and older with a recall period of 4 weeks. There are 17 items across 4 domains: functioning (4 items), fatigue/mood (5 items), fears/shame (6 items), and food (2 items). Responses use a 5-point Likert scale ranging from 'never' to 'very often.' Global scores range from 0 to 100 and scores by domains range from 0 to 100.
- Work Productivity and Activity Impairment: General Health (WPAI:GH) Score [ Time Frame: From enrollment up to 36 months (every 3 months) ]The WPAI:GH is a generic questionnaire to measure the effect of general health and symptom severity on work productivity and regular activities during the past 7 days. It can be self- or interviewer-administered to adults aged 18 years or older. This 6-item PRO covers work (5 items) and daily activities (1 item) using yes/no or numerical answers (number of hours). WPAI:GH outcomes are expressed as impairment percentages. An overall work productivity score (health or symptom) [%0WP], is calculated by multiplying the percentage of work time spent working (health or symptom) [% WTW] by the percentage productivity at work (health or symptom) [%PW]: %0WP = %WTW * %PW.
- Treatment Satisfaction (TSQM-9) Score [ Time Frame: From enrollment up to 36 months (every 3 months) ]The TSQM is a generic questionnaire to measure participants' satisfaction with medication using yes/no and 5- or 7- point Likert scale response options. It is a self-administered PRO designed for adults aged 18 years or older with a recall period of 2 to 3 weeks, or since the last medication use. Version TSQM-9 includes 3 domains: effectiveness (3 items), convenience (3 items), and global satisfaction scale (3 items). Scores range from 0 to 100.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||Child, Adult, Older Adult|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Probability Sample|
- Voluntarily provide written, signed, and dated (personally or via a legally-authorized representative) informed consent/and assent as applicable to participate in the study. Expression of understanding and agreement by fully informed parent(s) or legal guardian is required to permit the investigator to enroll a child in this study. The choice of the terms parental consent or parental permission in different regions may reflect local legal/regulatory and ethical considerations.
- Diagnosis of HAE Type I or Type II.
- Ability to use a mobile device for data collection in the study.
- Participation in any interventional clinical trial at the time of enrollment.
- Unable to provide written, signed, and dated informed consent/assent.
- Investigator believes that the participant is not a suitable candidate for the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03845400
|Study Director:||Study Director||Shire|
|Other Study ID Numbers:||
TAK-743-403 ( Other Identifier: Takeda Development Center Americas )
|First Posted:||February 19, 2019 Key Record Dates|
|Last Update Posted:||December 27, 2021|
|Last Verified:||December 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.|
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
|Access Criteria:||IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Skin Diseases, Vascular
Immune System Diseases
Hereditary Complement Deficiency Diseases
Primary Immunodeficiency Diseases
Genetic Diseases, Inborn
Immunologic Deficiency Syndromes